Switzerland already has various strategies in the health sector, such as the Cancer Plan, the NCD Strategy (noncommunicable diseases), the Vaccination Strategy, the Swiss Antibiotic Resistance Strategy (StAR) and the National programme: Stop HIV, hepatitis B and C viruses and sexually transmitted infections (NAPS). However, an overarching, holistic strategy with clear goals was missing until now.
Pharmaceutical companies not only develop new medicines and technologies – they also possess a wealth of knowledge regarding disease progressions, data analyses and the implementation of medical standards in clinical practice. In specific terms, this means:
A specific example is the Take CARE project, which focuses on optimally controlling risk factors for cardiovascular diseases. The project combines scientific findings and networking to improve the care of people with cardiovascular risks. As part of a multi-stakeholder partnership (consisting of PonteNet AG, KPT, Sanitas, Swica, the Institute of Primary Care Zurich and Novartis), a tool has been developed that enables doctors to implement medical guidelines with ease. It incorporates health parameters that are defined in the existing medical guidelines, for example LDL cholesterol levels and blood pressure. Such suitable monitoring of cardiovascular risk factors and subsequent guideline-compliant treatment is intended to improve the quality of treatment.
To Blog Part 1: Prevention as part of a sustainable Swiss healthcare system
To Blog Part 2: Targeted prevention and early detection are the key to long-term success
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2024
Introducing Interpharma
More about the tasks and overriding aims of Interpharma
Contact us
Latest information and media contacts for media representatives